A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 5200 participants.

Also called NCT06008197

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 5,200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06008197
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Brazil, Bulgaria, Canada, Croatia, Czechia, Germany, Greece, Hungary, India, Italy, Lithuania, Malaysia, Mexico, Peru, Poland, Portugal, Romania, Slovakia, South Korea, Spain, Sri Lanka, Taiwan, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06008197. Randomized; quadruple masking; primary purpose treatment. Start 2024-01-17 (actual); primary completion 2027-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Acronym
REDEFINE-HF
Condition
Heart Failure
Condition
Acute Heart Failure
Intervention (Drug)
Finerenone
Intervention (Drug)
Placebo
Lead sponsor
Colorado Prevention Center (class: other)
Collaborator
St. Luke's Hospital, Kansas City, Missouri (class: other)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct06008197
Content hash
ab635baca6207cb99890776581ab129da0ea59cf9268298105159cc6e2f71f02